CTLA4 and cancer: It has been proved that monoclonal antibody blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) immune checkpoint pathways and chimeric antigen receptor T cell therapy have achieved initial success in clinical treatment of cancer patients (Yang, 2015).